Strumento inattivo

Altre lingue Mirati Therapeutics

Azioni

MRTX

US60468T1051

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

British billionaire Joe Lewis intends to plead guilty to US charges, lawyer says	24/01
Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from S&P Biotechnology Select Industry Index	24/01
Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from S&P TMI Index	24/01
Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from S&P Global BMI Index	24/01
Bristol-Myers Squibb Closes Acquisition of Mirati Therapeutics	23/01
Bristol-Myers Squibb Closes Mirati Therapeutics Acquisition	23/01
Bristol Myers : acquisition de Mirati Therapeutics finalisée	23/01
Mirati Therapeutics, Inc. Announces Management Changes	23/01
Mirati Therapeutics, Inc.(NasdaqGM:MRTX) dropped from NASDAQ Composite Index	23/01
Bristol-Myers Squibb Company completed the acquisition of Mirati Therapeutics, Inc. from a group of shareholders.	23/01
Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index	22/01
Mirati Therapeutics - European Commission Approves KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation	11/01
Mirati Therapeutics' Krazati Lung Cancer Treatment Gets EU Conditional Marketing Authorization	10/01
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation	10/01
Bristol Myers expects to launch 16 new products through 2030 - CEO	08/01
Immunome Appoints Phil Roberts as Chief Technical Officer	04/01
Bristol-Myers Squibb koopt RayzeBio	26/12
US FDA turns down Amgen lung cancer drug Lumakras for full approval	26/12
Bristol-Myers Agrees Deal to Buy RayzeBio for About $4.1 Billion	26/12
Bristol Myers comprará a Karuna Therapeutics por 14.000 millones de dólares	22/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Mirati Therapeutics

Azioni

MRTX

US60468T1051

Altre lingue

Filtri